Docoh
Loading...

XNCR Xencor

APP
Utility
Bispecific Antibodies That Bind to CD38 and CD3
7 Oct 21
The invention provides novel heterodimeric proteins including heterodimeric antibodies.
Matthew Bernett, Seung Chu, Gregory Moore, John Desjarlais
Filed: 30 Oct 20
APP
Utility
HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
16 Sep 21
The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.
Matthew J. Bernett, Gregory L. Moore, John Desjarlais, Rumana Rashid
Filed: 12 Oct 20
APP
Utility
Fc VARIANTS WITH ALTERED BINDING TO FcRn
9 Sep 21
The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
Aaron Keith Chamberlain, Bassil Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
Filed: 23 Oct 20
GRANT
Utility
Heterodimeric antibodies that bind CD3 and tumor antigens
7 Sep 21
The present invention is directed to novel heterodimeric antibodies.
Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
Filed: 4 Apr 18
APP
Utility
Bispecific Immunomodulatory Antibodies That Bind Costimulatory and Checkpoint Receptors
19 Aug 21
The present invention is directed to bispecific, heterodimeric immunomodulatory antibodies.
Matthew J. Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon
Filed: 16 Apr 21
APP
Utility
Heterodimeric Antibodies That Bind Fibroblast Activation Protein
19 Aug 21
The present invention relates to novel antigen binding domains and heterodimeric antibodies that bind Fibroblast Activation Protein (FAP).
John Desjarlais, Alex Nisthal, Seung Chu
Filed: 16 Apr 21
GRANT
Utility
Modulation of T cells with bispecific antibodies and Fc fusions
17 Aug 21
The present invention relates to methods and compositions for modulating T cells.
Matthew Bernett, Seung Chu, Dilki Wickramarachichi, John Desjarlais
Filed: 8 Mar 19
GRANT
Utility
Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
10 Aug 21
The present invention is directed to a novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15Rα Fc fusion protein and an antigen binding domain Fc fusion proteins.
Matthew J. Bernett, John Desjarlais, Rajat Varma, Suzanne Schubbert, Juan Diaz
Filed: 2 Jul 18
APP
Utility
PD-1 Targeted IL-15/IL-15RALPHA FC Fusion Proteins with Improved Properties
29 Jul 21
The present invention relates to fusion proteins comprising variant IL-15 proteins, fusion proteins comprising variant anti-PD-1 antigen binding domains, and fusion proteins comprising variant IL-15 proteins and variant anti-PD-1 antigen binding domains.
John Desjarlais, Matthew Bernett, Michael Hedvat, Rajat Varma, Suzanne Schubbert, Christine Bonzon, Rumana Rashid, Juan Diaz, Patrick Holder, Christine Huang
Filed: 9 Oct 20
APP
Utility
Novel CTLA4-IG Immunoadhesins
29 Jul 21
The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
Gregory A. Lazar, Matthew J. Bernett
Filed: 15 Apr 21
APP
Utility
Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
8 Jul 21
The present application relates to therapeutic moieties displaying reduced immunogen response, particularly for therapeutic purposes.
John Desjarlais, Gregory L. Moore, Holly M. Horton
Filed: 10 Aug 20
GRANT
Utility
Optimized antibody variable regions
6 Jul 21
The present invention is directed to optimized anti-CD3 variable sequences for use in a variety of bispecific formats, including those that utilize scFv components.
Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
Filed: 16 Oct 18
APP
Utility
Fc VARIANTS THAT IMPROVE FcRn BINDING AND/OR INCREASE ANTIBODY HALF-LIFE
17 Jun 21
The present invention discloses the generation of novel variants of Fc domains, including those found in antibodies, Fc fusions, and immuno-adhesions, which have an increased binding to the FcRn receptor and/or increased serum half-life.
Gregory Alan Lazar
Filed: 19 Feb 21
APP
Utility
ANTI-STEAP1 Antigen-binding Protein
17 Jun 21
The disclosure provides novel antigen-binding proteins that bind STEAP1 and methods of use.
Olivier Nolan-Stevaux, Cong Li, Christopher M. Murawsky, Benjamin M. Alba, Neeraj Jagdish Agrawal, Kevin Graham, Jennitte LeAnn Stevens, Gregory Moore
Filed: 2 Jul 19
APP
Utility
Heterodimeric Proteins
10 Jun 21
In one aspect, the present invention provides heterodimeric antibodies comprising a first monomer comprising a first heavy chain constant domain comprising a first variant Fc domain and a first antigen binding domain and a second monomer comprising a second heavy chain constant domain comprising a second variant Fc domain and a second antigen binding domain.
Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
Filed: 2 Nov 20
APP
Utility
Fc VARIANTS THAT IMPROVE FcRn BINDING AND/OR INCREASE ANTIBODY HALF-LIFE
3 Jun 21
The present invention discloses the generation of novel variants of Fc domains, including those found in antibodies, Fc fusions, and immuno-adhesions, which have an increased binding to the FcRn receptor and/or increased serum half-life.
Gregory Alan Lazar
Filed: 21 Dec 20
APP
Utility
Novel Heterodimeric Proteins
3 Jun 21
The invention provides novel heterodimeric proteins including heterodimeric antibodies.
Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
Filed: 1 Jul 20
APP
Utility
OPTIMIZED Fc VARIANTS
13 May 21
The present invention relates to Fc variants having decreased affinity for FcγRIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
Gregory Lazar, Wei Dang, John Desjarlais, Sher Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
Filed: 29 Jul 20
APP
Utility
Fc VARIANTS WITH ALTERED BINDING TO FcRn
22 Apr 21
The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
Aaron Keith Chamberlain, Bassil Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
Filed: 25 Mar 20
APP
Utility
Fc VARIANTS WITH ALTERED BINDING TO FcRn
22 Apr 21
The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes.
Aaron Keith Chamberlain, Bassil Dahiyat, John Desjarlais, Sher Bahadur Karki, Gregory Lazar
Filed: 4 Aug 20
Patents are sorted by USPTO publication date, most recent first